Staff Publications: November 2018

  1. Abbas AE. Surgical Management of Lung Cancer: History, Evolution, and Modern Advances. Curr Oncol Rep. 2018;20(12):98. PMID: 30421260.
  2. Abboud CN, Lang N, Fung H, et al. Real-World Safety Experience of Tevagrastim/Ratiograstim/Biograstim and Tbo-Filgrastim, Short-Acting Recombinant Human Granulocyte Colony-Stimulating Factors. Support Care Cancer. 2018. PMID: 30443809.
  3. Ablain J, Xu M, Rothschild H, et al. Human Tumor Genomics and Zebrafish Modeling Identify SPRED1 Loss as a Driver of Mucosal Melanoma. Science. 2018;362(6418):1055-1060. PMID: 30385465.
  4. Anari F, O’Neill J, Choi W, et al. Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol. 2018;1(1):54-60. PMID: 30420974. PMC6226048. NIHMS966051
  5. Andersen MR, Karlan BY, Drescher CW, et al. False-Positive Screening Events and Worry Influence Decisions About Surgery among High-Risk Women. Health Psychol. 2018. PMID: 30431292.
  6. Andres SF, Williams KN, Plesset JB, et al. IMP1 3′ UTR Shortening Enhances Metastatic Burden in Colorectal Cancer. Carcinogenesis. 2018. PMID: 30407516.
  7. Asghar AM, McIntosh AG, Kutikov A, Chen DY, Geynisman DM. Neoadjuvant Chemotherapy for Penile Cancer Enabling Organ Preservation: A Case of Individualized Management for Bilateral Lymph Node Metastasis and a Bulky Primary Tumor. Urol Case Rep. 2019;23:3-5. PMID: 30505684. PMC6260424.
  8. Banerjee PP, Pang L, Soldan SS, et al. KIR2DL4-HLAG Interaction at Human NK Cell-Oligodendrocyte Interfaces Regulates IFN-γ-Mediated Effects. Mol Immunol. 2018. PMID: 30482463.
  9. Beitler JJ, Ridge JA, Vermorken JB, et al. T4 Laryngeal Cancer with Good Function: Should We Be Reluctant to Treat without Surgery? International Journal of Radiation Oncology Biology Physics. 2018;102(5):1400-1403.
  10. Beri N, Patrick-Miller LJ, Egleston BL, et al. Preferences for in-Person Disclosure: Patients Declining Telephone Disclosure Characteristics and Outcomes in the Multicenter Communication of Genetic Test Results by Telephone Study. Clin Genet. 2018. PMID: 30417332.
  11. Bevelacqua JJ, Mortazavi SMJ. Comments on “Irradiation Effects of MeV Protons on Dry and Hydrated Brassica rapa Seeds”. Life Sci Space Res (Amst). 2018;19:51. PMID: 30482281.
  12. Bevers TB, Helvie M, Bonaccio E, et al. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(11):1362-1389. PMID: 30442736.
  13. Blackman E, Ashing K, Gibbs D, et al. The Cancer Prevention Project of Philadelphia: Preliminary Findings Examining Diversity among the African Diaspora. Ethn Health. 2018:1-17. PMID: 30453751.
  14. Bleicher RJ, Chang C, Wang CE, et al. Treatment Delays from Transfers of Care and Their Impact on Breast Cancer Quality Measures. Breast Cancer Res Treat. 2018. PMID: 30443881.
  15. Bruinooge SS, Pickard TA, Vogel W, et al. Understanding the Role of Advanced Practice Providers in Oncology in the United States. Jaapa. 2018;31(12):1-12. PMID: 30489397.
  16. Campbell KS, Cohen AD, Pazina T. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol. 2018;9:2551. PMID: 30455698. PMC6230619. .
  17. Capo-Chichi CD, Cai KQ, Xu XX. Overexpression and Cytoplasmic Localization of caspase-6 Is Associated with Lamin a Degradation in Set of Ovarian Cancers. Biomark Res. 2018;6:30. PMID: 30450209. PMC6208109.
  18. Chang HW, Valieva ME, Safina A, et al. Mechanism of Fact Removal from Transcribed Genes by Anticancer Drugs Curaxins. Sci Adv. 2018;4(11):eaav2131. PMID: 30417101. PMC6221510.
  19. Chien CR, Geynisman DM, Kim B, Xu Y, Shih YT. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. Pharmacoeconomics. 2018. PMID: 30467701.
  20. Churilla TM, Chowdhury IH, Handorf E, et al. Comparison of Local Control of Brain Metastases with Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 30419088.
  21. Clark S, Ebersole B. Understanding the Role of Speech Language Pathologists in Managing Dysphagia. Nursing. 2018;48(12):42-46. PMID: 30461710.
  22. Collins ME, Abrahm JL. Communication Challenges at the Crossroads of Oncology and Palliative Care: Finding a Way Forward When Clinicians Differ on Prognosis. J Palliat Care. 2018:825859718814767. PMID: 30484363.
  23. Correa AF, Uzzo RG. Author Response. Urology. 2018.
  24. D’Avella C, Abbosh P, Pal SK, Geynisman DM. Mutations in Renal Cell Carcinoma. Urol Oncol. 2018. PMID: 30478013.
  25. Del Bene G, Calabro F, Giannarelli D, et al. Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis from the RISC Database. Front Oncol. 2018;8:463. PMID: 30510914. PMC6252384.
  26. Drilon A, Fu S, Patel MR, et al. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2018. PMID: 30487236.
  27. Edwards DC, Cahn DB, Smaldone MC, Kutikov A. Use of Administrative Data for Comparative Effectiveness Research in the Treatment of Non-Prostate Genitourinary Malignancies. Urol Oncol. 2018;36(4):193-212. PMID: 28867432.
  28. Fatkhullina AR, Peshkova IO, Dzutsev A, et al. An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity. 2018;49(5):943-957 e949. PMID: 30389414. PMC6257980. NIHMS1510832.
  29. Gasoyan H, Tajeu G, Halpern MT, Sarwer DB. Reasons for Underutilization of Bariatric Surgery: The Role of Insurance Benefit Design. Surg Obes Relat Dis. 2018. PMID: 30425002.
  30. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy Plus Cetuximab or Cisplatin in Human Papillomavirus-Positive Oropharyngeal Cancer (Nrg Oncology Rtog 1016): A Randomised, Multicentre, Non-Inferiority Trial. Lancet. 2018. PMID: 30449625.
  31. Hanada Y, Choi AY, Hwang JH, et al. Low Frequency of Lymph Node Metastases in Patients in the United States with Early-Stage Gastric Cancers That Fulfill Japanese Endoscopic Resection Criteria. Clin Gastroenterol Hepatol. 2018. PMID: 30471457.
  32. Handra-Luca A, Wei S. Intrathyroid Cystic Thyroglossal Duct Remnant and Ectopic Thymus: A Fortuitous or Development-Related Association? Surg Today. 2018;48(8):815-818. PMID: 29460127.
  33. Holschneider CH, Petereit DG, Chu C, et al. Brachytherapy: A Critical Component of Primary Radiation Therapy for Cervical Cancer: For the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS). Gynecol Oncol. 2018.
  34. Hopper JL, Dite GS, MacInnis RJ, et al. Age-Specific Breast Cancer Risk by Body Mass Index and Familial Risk: Prospective Family Study Cohort (Prof-Sc). Breast Cancer Res. 2018;20(1):132. PMID: 30390716. PMC6215632.
  35. Horwitz EM, Ridge JA, Bruner DW, Movsas B, Pollack A, Fowble B. Gerald E. Hanks, Md, Fastro Obituary. International Journal of Radiation Oncology Biology Physics. 2018;102(5):1393-1395.
  36. Hulse M, Caruso LB, Madzo J, Tan Y, Johnson S, Tempera I. Poly(ADP-Ribose) Polymerase 1 Is Necessary for Coactivating Hypoxia-Inducible Factor-1-Dependent Gene Expression by Epstein-Barr Virus Latent Membrane Protein 1. PLoS Pathog. 2018;14(11):e1007394. PMID: 30395643. PMC6237423.
  37. Ismail HM, Krishnamoorthy N, Al-Dewik N, et al. In Silico and in Vivo Models for Qatari-Specific Classical Homocystinuria as Basis for Development of Novel Therapies. Hum Mutat. 2018. PMID: 30408270.
  38. Karchugina S, Chernoff J. Detection of Heterodimerization of Protein Isoforms Using an in Situ Proximity Ligation Assay. J Vis Exp. 2018(140). PMID: 30394375. PMC6235567.
  39. Kijima T, Nakagawa H, Shimonosono M, et al. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. Cell Mol Gastroenterol Hepatol. 2019;7(1):73-91. PMID: 30510992. PMC6260338.
  40. Klingler MJ, Babitz SK, Kutikov A, et al. Assessment of Volume Preservation Performed before or after Partial Nephrectomy Accurately Predicts Postoperative Renal Function: Results from a Prospective Multicenter Study. Urol Oncol. 2018. PMID: 30473205.
  41. Liu JC, Bhayani M, Kuchta K, Galloway T, Fundakowski C. Patterns of Distant Metastasis in Head and Neck Cancer at Presentation: Implications for Initial Evaluation. Oral Oncology. 2019;88:131-136.
  42. Malik R, Luong T, Cao X, et al. Rigidity Controls Human Desmoplastic Matrix Anisotropy to Enable Pancreatic Cancer Cell Spread Via Extracellular Signal-Regulated Kinase 2. Matrix Biol. 2018. PMID: 30412725.
  43. Manley C, Olszanski A. Melanoma in the Bronchus. N Engl J Med. 2018;379(20):e36. PMID: 30428282. https://www.ncbi.nlm.nih.gov/pubmed/30428282.
  44. Masic S, Kutikov A. Robotic Inferior Vena Cava Thrombectomy: Are We Entering the House through an Attic Window? Eur Urol Focus. 2018. PMID: 30415922.
  45. Matulonis UA, Birrer MJ, O’Malley DM, et al. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. Clin Cancer Res. 2018. PMID: 30413525.
  46. Mortazavi SMJ. Re: Presence of Multidrug Resistant Bacteria on Mobile Phones of Healthcare Workers Accelerates the Spread of Nosocomial Infections and Regarded as a Threat to Public Health in Bangladesh. J Microsc Ultrastruct. 2018;6(4):215-216. PMID: 30464896. PMC6206753.
  47. Pei J, Al-Saleem T, Uzzo RG, Dulaimi E, Testa JR, Wei S. Application of Chromosome Microarray Analysis for the Differential Diagnosis of Low-Grade Renal Cell Carcinoma with Clear Cell and Papillary Features. Appl Immunohistochem Mol Morphol. 2018. PMID: 30499818.
  48. Ragin C, Banydeen R, Zhang C, et al. Breast Cancer Research in the Caribbean: Analysis of Reports from 1975 to 2017. J Glob Oncol. 2018(4):1-21. PMID: 30481085.
  49. Roach M, Moughan J, Lawton CAF, et al. Sequence of Hormonal Therapy and Radiotherapy Field Size in Unfavourable, Localised Prostate Cancer (NRG/RTOG 9413): Long-Term Results of a Randomised, Phase 3 Trial. Lancet Oncol. 2018;19(11):1504-1515. PMID: 30316827.
  50. Rogers HL, Dumenci L, Epstein RM, Siminoff LA. Impact of Patient Gender and Race and Physician Communication on Colorectal Cancer Diagnostic Visits in Primary Care. J Womens Health (Larchmt). 2018. PMID: 30489201.
  51. Shafi AA, Schiewer MJ, de Leeuw R, et al. Patient-Derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol. 2018;1(4):325-337. PMID: 30467556. PMC6241309. NIHMS972310.
  52. Streiff MB, Holmstrom B, Angelini D, et al. Nccn Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289-1303. PMID: 30442731.
  53. Terry MB, Daly MB, Phillips KA, et al. Risk-Reducing Oophorectomy and Breast Cancer Risk across the Spectrum of Familial Risk. J Natl Cancer Inst. 2018. PMID: 30496449.
  54. Tomalka AG, Resto-Garay I, Campbell KS, Popkin DL. In Vitro Evidence That Combination Therapy with CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2HI Memory T Cells. Front Immunol. 2018;9:2552. PMID: 30455699. PMC6230627.
  55. Tripathi A, Plimack ER. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Curr Urol Rep. 2018;19(12):109. PMID: 30406502.
  56. Vrakas CN, Herman AB, Ray M, Kelemen SE, Scalia R, Autieri MV. Rna Stability Protein ILF3 Mediates Cytokine-Induced Angiogenesis. FASEB J. 2018:fj201801315R. PMID: 30383449.
  57. Zhang H, Pandey S, Travers M, et al. Targeting Cdk9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 2018;175(5):1244-1258 e1226. PMID: 30454645. PMC6247954. NIHMS1510720.

Read More »

Advertisements

Is this Journal Legitimate?

Every now and then someone forwards an email from a publisher inviting him or her or them to review submissions, submit an article, or be on the editorial board of a journal. I start reading and three things jump out at me:

  • Reputable journals and conferences don’t email you out of the blue.
  • This email is not very well written.
  • Considering that the representative from this journal is contacting this clinician/researcher for the first time, it’s very informal.

There have been unscrupulous publishers for as long as there have been publishers. They are in the minority but their numbers are growing, and they are becoming more sophisticated. The following are some of the things we look for:

The Journal

  • Does the journal have an valid ISSN?
    • Why does this matter? When a publisher applies for an ISSN, they must provide information and supporting documentation to the ISSN International Centre including: title, frequency, publisher’s name, and medium along with copies of the title page, cover page, editorial page, PDF or JPG of the jacket (if the publication is on CD-ROM), and the URL if the journal is online. Publishers can apply for an ISSN in advance of publication. If the journal does not have an ISSN, be wary of the publisher.
  • Is the current issue available online?
    • Are any back issues available online? If so, does the content look credible? Do you recognize any of the authors?
  • Are their copyright policies, open access policies (where applicable), and peer-review policies and processes explained clearly?
    • More and more predatory journals are putting these policies online. Make sure they make sense and weigh them carefully against other factors, like lacking an ISSN.
  • If the journal boasts an Impact Factor or an Eigenfactor, can it be verified through Journal Citation Reports or Eigenfactor.org, respectively?
    • The Talbot Library subscribes to Journal Citation Reports. The Eigenfactor can be verified at Eigenfactor.org.
  • If the journal claims to be indexed in a particular database (PubMed, Web of Science, SCOPUS, EMBASE) search any or all of those databases to verify the claim.
    • Unscrupulous publishers have been known to create false indexes and claim their journal is indexed there. Something else to keep in mind is every once in a while an article from a predatory journal does make its way into a database.

The Publisher

  • Does the publisher provide full, verifiable contact information including the street address, a working email address, and a working telephone number either in the email message or on the Web site?
    • If you are unsure of the publisher’s veracity, you are well within your rights to phone or email. I prefer phoning, myself. Last time I phoned a questionable publisher, I was bounced into a random, numbered voicemail.
  • If the journal charges publication fees, are they stated up-front and explained clearly?
  • Does the publisher have a Web site? Are the pages within that site stable?
  • On the Web site, check for language use, grammatical errors, and typographical errors. Is the language stilted? Overly formal? Strangely inappropriate?
    • I once ran across a publisher who took great pains to state that they were an American publishing organization, as opposed to an American publisher. Yet they used the British spelling of gynecological.
    • This same publisher described a nursing journal as follows, “Nursing, the word itself reflects a “care” in it and can be treated as the most divine and dedicated professional science that helps patients in the severely ill circumstances from the time of birth till death.”
  • Is the publisher listed in Ulrich’s or  SHERPA/Romeo?
    • Ulrich’s and SHERPA/Romeo will tell you where a publisher is headquartered, where a journal is indexed, how often new issues are released (frequency), and more. SHERPA/Romeo is available free online but ask one of us in the library to search Ulrich’s.

What can I do?

  • Be very wary of unsolicited contact from a publisher with whom you are not familiar.
  • Don’t agree to review submissions, submit articles, or join an editorial board of a journal you do not recognize.
  • Check any claims made by the publisher, be they impact factor, member of an editorial board, or incluion in an index or database like Web of Science or PubMed.
  • Keep your online presence current and accurate.
    • Keeping your professional information up to date makes it easier for others to do the due diligence when they are researching a suspect journal.
  • Have you been fooled by a predatory publisher, tell your colleagues.
  • When in doubt about a journal, publisher, or conference, talk to a librarian.
    • Librarians are trained to find and evaluate information. If you have doubts come talk to us, we can look into the publisher for you.

New Open Access Journals

In honour of the 8th annual International Open Access Week, several publishers have released new open access titles that may be of interest. The following titles have been added to our collection and can be access from the Talbot Library Journal Holdings page.

  • Molecular Case Studies (Cold Spring Harbor Laboratory Press):  Molecular Case Studies is a new, open-access international journal in the field of precision medicine. Articles present genomic and molecular analyses of individuals or cohorts alongside clinical and phenotypic information. The aim is to share insights into disease development and treatment gained by application of genomics, metabolomics, and other data-driven approaches.
  • Journal of Global Oncology (ASCO):  Journal of Global Oncology is  focused on cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources.  Article types include original reports, review articles, commentaries, correspondence/replies, special articles and editorials.
  • Case Reports in Pancreatic Cancer (Mary Ann Liebert): Case Reports in Pancreatic Cancer is an open access journal that publishes case reports on all aspects of pancreatic cancer including diagnosis, management, treatment, and outcomes.  The first issue is in progress.
  • Journal of Endourology Case Reports (Mary Ann Liebert): Journal of Endourology Case Reports is an open access journal that publishes clinically interesting and educational case reports on the treatment and surgical management of urologic diseases.
  • Transgender Health (Mary Ann Liebert): Transgender Health is the first peer-reviewed, open access journal dedicated to addressing the healthcare needs of transgender individuals throughout the lifespan and identifying gaps in knowledge as well as priority areas where policy development and research are needed to achieve healthcare equity. The first issue is in progress.

New edition of Journal Citation Report (JCR) available

The latest edition (2008) of Journal Citation Reports is now available. This is the tool that configures journal impact factors. To access it, go to the Talbot Research Library’s A to Z list and click on Journal Citation Reports or click here.

The latest edition delivers:

  • 350+ titles with a Journal Impact Factor for the first time
  • First ever update to new metrics: Five Year Impact Factors and Eigenfactor™ Metrics (available only in JCR® Web)
  • Over 400 new titles in the Science and Social Sciences Editions
  • More than 8,000 of the world’s most highly cited, peer-reviewed journals
  • Journals from 3,300 publishers in approximately 227 disciplines, from 60 countries
  • The largest time-trend analyses ever available